Compare AbbVie Inc (ABBV) vs Iris Energy Limited (IREN) Price & Performance

ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.

Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.

IREN trades at $41.23, up 8.7% in the past 24 hours, with a bearish technical signal and RSI near 80 indicating potential overbought conditions. The company reported Q1 2026 revenue of $501 million and net income of $87 million, but missed EPS estimates for three consecutive quarters. Recent news highlights $2.8 billion in new AI contracts and a raised revenue target above $4 billion, signaling strong growth prospects in AI infrastructure.

The outlook is mixed: analyst consensus is bullish with a $84.43 price target, but high valuation ratios and earnings misses pose risks. Investment opportunity lies in AI contract growth, while risks include execution challenges and competitive pressures in the neocloud market.